Guangzhou, China– August , 2024 – Inc. “The EC approval of BAT2206 is anothersignificant accomplishment for Bio-Thera as it marks Bio-Thera’s third EC approvedproduct” said Shengfeng Li, CEO at Bio-Thera. “Bio-Thera is committed toexpanding access fo...
View DetailsGuangzhou, China– April 14, 2025 –Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical companydeveloping a pipeline of innovative therapies and biosimilars, will have anoral presentation in collaboration with medical centers at ...
Guangzhou, China/ Hyderabad, India – March 26,2025 – Bio-Thera Solutions (688177:SH; “Bio-Thera”), a commercial-stagebiopharmaceutical company developing a pipeline of innovative therapies andbiosimilars, and Dr. Reddy’s Laboratories SA, wholly-owned...
GUANGZHOU, China --- Bio-Thera Solutions (688177:SH), a commercial-stagebiopharmaceutical company developing a pipeline of innovative therapies and biosimilars,today announced the companyhas reached an exclusivecommercialization and license agreement...